Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059322 | 0.90 | TDP2 (0.40) | MAPTTP53TDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4528741 | 0.76 | GAA (0.40) | ALDH1A1USP2GAAMEN1KMT2A | |
| SCHEMBL6692386 | 0.65 | USP2 (0.36) | TP53TDP1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4386782 | 0.61 | ALDH1A1 (0.40) | MAPTALDH1A1TDP2HSD17B10USP2 | |
| SCHEMBL23714843 | 0.61 | HPGD (0.33) | MAPTHTTMEN1KMT2A | |
| SCHEMBL9667216 | 0.60 | KMT2A (0.46) | MAPTTDP1ALDH1A1TSHRLMNA | |
| SCHEMBL19798778 | 0.60 | MAPT (0.34) | MAPTTP53CYP1B1LMNA | |
| SCHEMBL9667378 | 0.60 | CASP3 (0.48) | MAPTSMN1; SMN2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL9667758 | 0.59 | USP2 (0.43) | TP53TDP1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL22655353 | 0.58 | MEN1 (0.59) | MAPTTP53TDP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| CN-1914206-A | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-02-14 | — | — | CN | disclosed |
| US-20050182085-A1 | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | SLC5A2, SLC5A1, SLC2A2 | MAPT 4750/4885TP53 2634/4885TDP1 3737/4885 |
| US-20050182085-A1 | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SLC5A2, CYP2A7, GLS | MAPT 4230/4885TP53 1877/4885TDP1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.